Equities

Prophase Labs Inc

PRPH:NAQ

Prophase Labs Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.7145
  • Today's Change-0.023 / -3.13%
  • Shares traded316.34k
  • 1 Year change-84.24%
  • Beta-0.2869
Data delayed at least 15 minutes, as of Nov 13 2024 17:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.

  • Revenue in USD (TTM)17.97m
  • Net income in USD-26.31m
  • Incorporated2015
  • Employees113.00
  • Location
    Prophase Labs Inc711 STEWART AVE, SUITE 200, GARDEN CITYNEW YORK 11530United StatesUSA
  • Phone+1 (215) 345-0919
  • Websitehttps://www.prophaselabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pacific Health Care Organization Inc6.17m869.09k10.75m30.0012.390.943911.871.740.06780.06780.48120.890.5259--6.40205,557.707.417.297.937.8179.0382.7514.0913.28----0.00---2.00-3.7055.80-10.80-15.93--
ATI Physical Therapy Inc741.86m-79.62m10.81m6.00k------0.0146-18.57-18.57174.1717.200.7625--8.02123,643.80-5.49---6.39--16.13---7.21----0.19050.8762--9.97--73.20------
Streamline Health Solutions Inc20.30m-18.82m11.02m77.00--10.39--0.5428-0.3277-0.32770.34990.25110.4397--7.64263,636.40-40.77-22.06-56.63-31.6950.8649.96-92.72-54.55---4.460.4395---9.210.2057-64.31---11.72--
Interpace Biosciences Inc44.89m4.89m13.17m108.002.71--2.550.29341.101.0610.13--------415,675.90---38.19---69.7360.4649.4410.88-41.01--8.11----26.3112.93118.96--0.9184--
Aesthetic Medical Intl Hldg Grp Ltd(ADR)100.48m-6.70m13.42m1.29k--3.486.770.1336-0.1486-0.14862.220.08061.2920.8277.3678,133.28-9.06-23.36-35.45-48.5845.3955.32-7.02-23.720.2031-5.500.9581--1.86-2.1650.91--3.70--
Elite Health Systems Inc0.00-1.02m13.48m2.00--6.75-----0.0928-0.09280.000.14820.00----0.00-45.80-14.62-66.91-19.89-------36.77----0.00------38.97------
Psychemedics Corp.20.79m-4.56m13.76m116.00--2.37--0.6621-0.7882-0.78823.590.98581.57--5.89179,198.30-34.41-7.44-53.29-9.7037.6337.55-21.93-6.26---264.690.1198---12.45-12.33-283.21---33.32--
PharmChem Inc5.98m1.14m14.97m170.0013.345.4513.122.500.24140.24141.260.59031.839.258.71--34.87--42.91--64.49--19.05--5.20--0.00--3.50---16.95------
ProPhase Labs Inc17.97m-26.31m17.15m113.00--0.3193--0.9542-1.46-1.460.99622.310.19465.240.5027159,044.30-28.480.9106-36.781.12-9.1150.32-146.390.93251.44-17.990.2469665.78-63.8127.59-190.90--86.46--
Oncology Institute Inc361.07m-58.51m21.89m800.00--0.7496--0.0606-0.7898-0.78984.870.38691.7626.037.19451,333.80-34.94---41.97--15.3319.54-19.81-9.992.99-7.800.7549--28.4223.43-99,919.12--45.68--
Concord Medical Services Hldgs Ltd (ADR)65.22m-52.40m22.01m727.00------0.3375-11.99-11.9914.93-68.110.074313.395.3589,716.46-10.23-9.49-111.95-39.24-17.13-15.06-137.67-134.560.4556-1.890.6369--13.8423.0039.21---6.88--
Data as of Nov 13 2024. Currency figures normalised to Prophase Labs Inc's reporting currency: US Dollar USD

Institutional shareholders

7.90%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2024651.89k3.42%
Renaissance Technologies LLCas of 30 Jun 2024220.51k1.16%
Hightower Advisors LLCas of 30 Jun 2024151.37k0.79%
Geode Capital Management LLCas of 30 Jun 2024147.15k0.77%
Perritt Capital Management, Inc.as of 30 Jun 202485.50k0.45%
BlackRock Fund Advisorsas of 30 Jun 202461.05k0.32%
Chapin Davis, Inc. (Investment Management)as of 30 Sep 202450.00k0.26%
swisspartners AGas of 30 Jun 202450.00k0.26%
Susquehanna Financial Group LLLPas of 30 Jun 202445.97k0.24%
SSgA Funds Management, Inc.as of 30 Jun 202444.66k0.23%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.